Biliary Tract Carcinoma Clinical Trial
Official title:
A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer
Verified date | February 2018 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I study (an early study to check the safety of a new drug or drug
combination) to find the safest and most tolerated dose of the combination of oxaliplatin
with gemcitabine and MEK 162 in patients with biliary cancer (including gallbladder cancers
and cancers associated with the bile ducts leading from the gallbladder and to and from the
liver) that is not curable by surgery and/or has spread beyond the biliary tree (place where
cancer started). Everyone will receive the same standard doses of oxaliplatin and gemcitabine
but may receive different doses of MEK 162.
MEK 162 is a new drug which plays an important role in the regulation of cell growth and has
been shown to shrink tumours in patients with biliary cancer and other types of human
cancers. This type of drug has also been shown to shrink tumours when given in combination
with cisplatin and gemcitabine in research studies done in animals and in some patients with
biliary cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histopathological or cytological diagnosis of non-resectable, recurrent or metastatic biliary tract (intra- or extra-hepatic) or gallbladder carcinoma. - Have measurable disease. - Not received prior systemic therapy for advanced biliary cancer. - Age 18 years of age or older. - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. - Estimated life expectancy is greater than 3 months. - Have adequate hematological function. - Have adequate cardiac function. - All radiology studies performed within 4 weeks prior to the start of therapy. - No evidence of active uncontrolled infection. - Ability to understand and willing to sign a written informed consent document. - Ongoing prior toxicities related to previous treatments received to grade 1 or less at time of registration. - Able to take oral medications. Exclusion Criteria: - Progressing within 6 months of receiving adjuvant treatment for biliary tract cancer. - Not have received prior chemotherapy for non-resectable or metastatic disease or MEK inhibitor. - Histopathological or cytological diagnosis of ampullary carcinoma. - Incomplete recovery from previous surgery. - Undergoing current treatment with curative intent. - History of prior malignancy that could interfere with the response evaluation. - Any evidence of severe or uncontrolled systemic diseases or laboratory findings that may affect participation in the trial. - Any psychiatric or other disorder likely to impact on informed consent. - Pregnant or nursing (lactating) women. - Agree to use highly effective methods of contraception throughout the study and for 6 months after study drug discontinuation. - Significant cardiac disease. - History of retinal degenerative disease. - History of Gilbert's syndrome. - Known positive serology for HIV, active hepatitis B, and/or active hepatitis C infection. - Neuromuscular disorders that are associated with elevated creatine kinase. - Planning on embarking on a new strenuous exercise regimen after first dose of study treatment. - Impairment of gastrointestinal function or gastrointestinal disease. - Any other condition that would contraindicate participation in the clinical study due to safety concerns or compliance with clinical study procedures. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total incidence of grade 3 and 4 adverse events | 2 years | ||
Primary | Total rate of grade 3 and 4 adverse events | 2 years | ||
Primary | Maximum dose level at which 0/3 patients or 1/6 patients experience dose-limiting toxicity | 2 years | ||
Secondary | Number of patients with objective response rate | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04003896 -
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04003636 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
|
Phase 3 | |
Not yet recruiting |
NCT05064852 -
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
|
||
Recruiting |
NCT05668884 -
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
Recruiting |
NCT05123482 -
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
Recruiting |
NCT06048133 -
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
|
Phase 2 | |
Recruiting |
NCT05845554 -
Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
|
||
Completed |
NCT00490399 -
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
|
Phase 2 | |
Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT06430827 -
Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma
|
Phase 2 | |
Recruiting |
NCT06047990 -
Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction
|
N/A | |
Active, not recruiting |
NCT04924062 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06463548 -
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
|
N/A | |
Terminated |
NCT04178460 -
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
|
Phase 1 | |
Completed |
NCT03027284 -
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06199882 -
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05023109 -
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
|
Phase 2 | |
Not yet recruiting |
NCT06168292 -
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
|
N/A | |
Recruiting |
NCT04979663 -
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
|
Phase 1/Phase 2 |